CSF proteins and resting-state functional connectivity in Parkinson disease

Neurology

Volumn 84, Issue 24, 2015, Pages 2413-2421

  Campbell, Meghan C ^a   Koller, Jonathan M ^a   Snyder, Abraham Z ^a   Buddhala, Chandana ^a   Kotzbauer, Paul T ^a   Perlmutter, Joel S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT; SNCA PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATTENTION; BIOACCUMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEFAULT MODE NETWORK; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; RESTING STATE NETWORK; SALIENCE NETWORK; SENSORIMOTOR FUNCTION; BRAIN; BRAIN MAPPING; CEREBROSPINAL FLUID; MIDDLE AGED; MOTOR ACTIVITY; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PUNCTURE; REST; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEURAL PATHWAYS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REST; SEVERITY OF ILLNESS INDEX; SPINAL PUNCTURE; THIAZOLES;

EID: 84931082558     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001681     Document Type: Article

References (40)

1. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alpha-synuclein and A beta in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326-1331.
2. Wu T, Wang L, Chen Y, Zhao C, Li K, Chan P. Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. Neurosci Lett 2009;460:6-10.
3. Wu T, Long X, Wang L, et al. Functional connectivity of cortical motor areas in the resting state in Parkinson's disease. Hum Brain Mapp 2011;32:1443-1457.
4. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, Toni I. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb Cortex 2010;20:1175-1186.
5. Esposito F, Tessitore A, Giordano A, et al. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. Brain 2013;136:710-725.
6. Szewczyk-Krolikowski K, Menke RA, Rolinski M, et al. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology 2014;83:208-214.
7. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012;135:3699-3711.
8. Luo C, Song W, Chen Q, et al. Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study. Neurobiol Aging 2014;35:431-441.
9. Tessitore A, Esposito F, Vitale C, et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology 2012;79:2226-2232.
10. Shine JM, Halliday GM, Gilat M, et al. The role of dys functional attentional control networks in visual misper-ceptions in Parkinson's disease. Hum Brain Mapp 2014;35:2206-2219.
11. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
12. Sperling RA, LaViolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63:178-188.
13. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebro-spinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
14. Wang L, Brier MR, Snyder AZ, et al. Cerebrospinal fluid Abeta42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol 2013;70:1242-1248.
15. Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO. Ratio of Abeta42/P-tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep 2013;3:1339.
16. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF alpha-synuclein and Abeta in Parkinson disease. Neurobiol Aging 2015;36:476-484.
17. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drugnaive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
18. Van Dijk KRA, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional connectivity MRI. Neuroimage 2012;59:431-438.
19. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012; 59:2142-2154.
20. Raichle ME. The restless brain. Brain Connect 2011;1:3-12.
21. Brier MR, Thomas JB, Snyder AZ, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci 2012;32:8890-8899.
22. Di Martino A, Scheres A, Margulies DS, et al. Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex 2008;18:2735-2747.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neuro-surg Psychiatry 1992;55:181-184.
24. Luo C, Chen Q, Song W, et al. Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression. J Neurol Neurosurg Psychiatry 2014;85:675-683.
25. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item Geriatric Depression Scale and Hamilton Depression Rating Scale in Parkinson disease. Am J Geriatr Psychiatry 2006;14:169-175.
26. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
27. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
28. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent Developments in Parkinson's Disease. New York: Macmillan; 1987:153-163.
29. Campbell MC, Markham J, Flores H, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013;81:520-527.
30. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;15:2516-2523.
31. Mintun MA, LaRossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
32. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
33. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724-738.
34. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988;111:323-345.
35. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 2005;102:9673-9678.
36. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1-11.
37. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014;137:1496-1513.
38. Diogenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;32:11750-11762.
39. Walsh DM, Selkoe DJ. A beta oligomers: a decade of discovery. J Neurochem 2007;101:1172-1184.
40. Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 2012;263:226-234.